Novelix Pharma. — 360° view

Novelix Pharma, a company in the Healthcare Research, Analytics & Technology industry, reported revenue of ₹45 crore and net profit of ₹1.56 crore for the September 2026 quarter.

Novelix Pharma. (BSE: NOVELIX) closed at ₹65.34 on 20 Nov 2026, up 8.3% over the past year. Its market capitalisation is ₹186 crore and it trades at 40.0 times earnings.

Share price
₹65.34 (20 Nov 2026)
Market cap
₹186 Cr (20 Nov 2026)
P/E
40.01 (20 Nov 2026)
Revenue
₹45 Cr (September 2026 quarter)
Net profit
₹2 Cr (September 2026 quarter)
ROCE
10.9% (FY26)
ROE
8.00% (FY26)
Book value
₹23.0 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹92.00 / ₹49.01 (20 Nov 2026)
1-year return
8.3% (to 20 Nov 2026)
Sector
Healthcare
Industry
Healthcare Research, Analytics & Technology
Symbol
BSE: NOVELIX

Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.